Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
May 9, 2017 7:00 AM EDTLAVAL, Quebec, May 9, 2017 /PRNewswire/ --
First Quarter Financial Results Revenues of $2.109 Billion GAAP Net Income of $628 Million GAAP Cash Flow from Operations of $954 Million Adjusted EBITDA (non-GAAP) of $861 Million Adjusted Net Income (non-GAAP) of $273 Million Reduced Debt by $1.3 Billion in the quarter Raising 2017 Full Year Adjusted EBITDA Guidance RangeMay 9, 2017 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)... More
